2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - La Nouvelle C
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Study Population, Human, Animal Model
PAPER

688 Effector T cell dependence of T cell engager activity drives depletion of viral-reactive CD8⁺ CX3CR1⁺ T cells and impairs antiviral immunity

Mansour Poorebrahim, PhD, David Jung, BSc2, Sungwoo Ahn, PhD3, Holly Lee, MD, PhD4, Motamed Mahmoud, PhD5, Sacha Benaoudia, PhD6, Noemie Leblay, PhD7, Takeshi Yoroidaka, MD, PhD8, Sae Matsuoka9, Elyad Babaei, N/A10, Anja Barbour11, Lorenzo Lindo, BSc12, Hermann Einsele, MD, PhD13, Leo Rasche Jr, MD14, Paola Neri, MD, PhD15, Nizar Bahlis, MD16
1 University of Calgary, Calgary, Canada
2 University of Calgary, Calgary, Canada
3 University of Calgary, Calgary, Canada
4 University of Calgary, Calgary, Canada
5 University of Calgary, Calgary, Canada
6 University of Calgary, Calgary, Canada
7 University of Calgary, Calgary, Canada
8 University of Calgary, Calgary, Canada
9 University of Calgary, Calgary, Canada
10 University of Calgary, Calgary, Canada
11 University of Calgary, Calgary, Canada
12 University of Calgary, Calgary, Canada
13 University Hospital of Würzburg, Würzburg, Germany
14 University Hospital of Würzburg, Würzburg, Germany
15 University of Calgary, Calgary, Canada
16 University of Calgary, Calgary, Canada

Background: T-cell engagers (TCEs) induce deep responses in multiple myeloma (MM) but are associated with increased susceptibility to recurrent viral infections. To date, the contribution of distinct T cell subsets to TCE-mediated antitumor activity remains poorly defined. We previously identified CD8? CX3CR1? T cells as a highly differentiated effector subset enriched during TCE therapy and associated with favorable clinical outcomes (PMID: 36898378). Here, we investigated their contribution to TCE efficacy and whether chronic TCE activation depletes viral-reactive CD8? CX3CR1? T cells, impairing antiviral immunity beyond plasma cells depletion.

Methods: To define the T cell subsets mediating TCE activity, naïve (Tn), effector-memory (Tem), CD4?, and CD8? T cells from healthy donors were sorted based on CD62L and CD45RA expression and assessed for Teclistamab-induced anti-myeloma function. The antitumor and antiviral properties of CX3CR1? and CX3CR1? T cell subsets from healthy donors and MM patients were evaluated using tumor-killing assays, cytokine profiling, and peptide-specific recall responses to CEF pool. Longitudinal peripheral blood samples from TCE-treated MM patients (n=36) with a median of 3 samples per patient were collected pre-, 3 months post and at disease progression were subjected to CITE-seq coupled with VDJ TCR sequencing to track CD8? CX3CR1? T cell dynamics, evaluate virally reactive clonotypes contraction and recovery and their temporal relationship to clinical viral infections.

Results: Tem cells demonstrated significantly superior TCE-mediated cytotoxicity compared with Tn cells across multiple Teclistamab concentrations. This was further validated in patient-derived samples, where a higher proportion of Tem cells was associated with enhanced killing function. Similarly, CD8+ T cells showed greater tumor killing relative to CD4+ T cells. However, phenotypic analysis revealed that this difference was primarily driven by subset composition, as CD8+ T cells were predominantly Tem whereas CD4+ T cells were enriched for Tn cells. Notably, CD4+ Tem and CD8+ Tem subsets exhibited comparable killing capacity, indicating that effector-like differentiation state rather than CD4/CD8 lineage is the dominant determinant of TCE responsiveness.

Mechanistically, Tn cells exhibited higher inhibitory Lck phosphorylation (pY505) than Tem cells, consistent with a more restrained TCR signaling state that may require differentiation toward a more effector-like state for efficient TCE-mediated killing. Supporting the importance of effector differentiation, IL-2 substantially enhanced Teclistamab-mediated antitumor activity of Tn cells and promoted their differentiation toward an effector-like state more efficiently than co-cultures with tumor-cells alone. CD8? CX3CR1? T cells displayed the strongest TCE-mediated antitumor activity, accompanied by enhanced activation, production of cytotoxic mediators (including granzymes, perforin, IFNγ, TNFα, and soluble FASL), and robust virus-specific recall responses. However, despite their potent effector function, CD8? CX3CR1? T cells were susceptible to activation-induced cell death and exhibited limited recovery following TCE-mediated tumor cell killing. This activation induced cell death may contribute to the progressive loss of viral-reactive CD8? CX3CR1? T cells during prolonged TCE therapy. Consistent with this, sorted CD8? CX3CR1? T cells from TCE-treated patients with recurrent viral infections exhibited markedly impaired responses to CEF peptide stimulation, compared to TCE treated patients without viral infections. Longitudinal single-cell transcriptomic and TCR analyses further demonstrated contraction of the viral-reactive CD8? CX3CR1? compartment, with increased TCR clonality, reduced repertoire diversity, and loss of virus-reactive clonotypes, including CMV-specific TCRs, during therapy.

Conclusions: Our findings identify CD8? CX3CR1? T cells as a critical effector population that bridges antitumor and antiviral immunity. While TCE therapy preferentially relies on these highly functional cells for tumor control, sustained activation drives their attrition, resulting in loss of virus-reactive cellular immunity and increased susceptibility to viral infections. These results provide mechanistic insight into anti-viral immune dysfunction associated with TCE therapy and may inform future strategies to preserve antiviral immunity while maintaining antitumor efficacy.

David Jung, BSc: No relevant conflicts of interest to declare.